Breast cancer (BC) is a heterogeneous disease, including different subtypes having diverse incidence, drug-sensitivity and survival rates. In particular, claudin-low and basal-like BC have mesenchymal features with a dismal prognosis. Disialoganglioside GD2 is a typical neuroectodermal antigen expressed in a variety of cancers. Despite its potential relevance in cancer diagnostics and therapeutics, the presence and role of GD2 require further investigation, especially in BC. Therefore, we evaluated GD2 expression in a cohort of BC patients and its correlation with clinical-pathological features.Sixty-three patients with BC who underwent surgery without prior chemo- and/or radiotherapy between 2001 and 2014 were considered. Cancer specimens were analyzed by immunohistochemistry and GD2-staining was expressed according to the percentage of positive cells and by a semi-quantitative scoring system.Patient characteristics were heterogeneous by age at diagnosis, histotype, grading, tumor size, Ki-67 and receptor-status. GD2 staining revealed positive cancer cells in 59% of patients. Among them, 26 cases (41%) were labeled with score 1+ and 11 (18%) with score 2+. Notably, the majority of metaplastic carcinoma specimens stained positive for GD2. The univariate regression logistic analysis revealed a significant association of GD2 with triple-receptor negative phenotype and older age (> 78) at diagnosis.We demonstrate for the first time that GD2 is highly prevalent in a cohort of BC patients clustering on very aggressive BC subtypes, such as triple-negative and metaplastic variants.
GD2 expression in breast cancer / Orsi, Giulia; Barbolini, Monica; Ficarra, G; Tazzioli, Giovanni; Manni, Paola; Petrachi, Tiziana; Mastrolia, Ilenia; Orvieto, E; Spano, Maria Carlotta; Prapa, Malvina; Kaleci, Shaniko; D'Amico, Roberto; Guarneri, V; Dieci, Mv; Cascinu, Stefano; Conte, P; Piacentini, Federico; Dominici, Massimo. - In: ONCOTARGET. - ISSN 1949-2553. - 8:19(2017), pp. 31592-31600.
Data di pubblicazione: | 2017 |
Titolo: | GD2 expression in breast cancer. |
Autore/i: | Orsi, Giulia; Barbolini, Monica; Ficarra, G; Tazzioli, Giovanni; Manni, Paola; Petrachi, Tiziana; Mastrolia, Ilenia; Orvieto, E; Spano, Maria Carlotta; Prapa, Malvina; Kaleci, Shaniko; D'Amico, Roberto; Guarneri, V; Dieci, Mv; Cascinu, Stefano; Conte, P; Piacentini, Federico; Dominici, Massimo |
Autore/i UNIMORE: | |
Digital Object Identifier (DOI): | http://dx.doi.org/10.18632/oncotarget.16363 |
Rivista: | |
Volume: | 8 |
Fascicolo: | 19 |
Pagina iniziale: | 31592 |
Pagina finale: | 31600 |
Codice identificativo ISI: | WOS:000401003200078 |
Codice identificativo Scopus: | 2-s2.0-85019096580 |
Codice identificativo Pubmed: | 28415563 |
Citazione: | GD2 expression in breast cancer / Orsi, Giulia; Barbolini, Monica; Ficarra, G; Tazzioli, Giovanni; Manni, Paola; Petrachi, Tiziana; Mastrolia, Ilenia; Orvieto, E; Spano, Maria Carlotta; Prapa, Malvina; Kaleci, Shaniko; D'Amico, Roberto; Guarneri, V; Dieci, Mv; Cascinu, Stefano; Conte, P; Piacentini, Federico; Dominici, Massimo. - In: ONCOTARGET. - ISSN 1949-2553. - 8:19(2017), pp. 31592-31600. |
Tipologia | Articolo su rivista |
File in questo prodotto:
File | Descrizione | Tipologia | |
---|---|---|---|
Orsi G et al. GD2 & BC Oncotarget 2017.pdf | Articolo principale | Versione dell'editore (versione pubblicata) | Open Access Visualizza/Apri |

I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris